H.C. Wainwright lowered the firm’s price target on Myomo (MYO) to $5 from $9.50 and keeps a Buy rating on the shares. The firm says that while the company’s Q2 ended well, there are warning signs ahead as Myomo reported that the number of patients added to its pipeline was significantly lower than expected.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYO: